Get started
Viking Therapeutics, Inc.Viking Therapeutics, Inc.Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

VKTX chart


Full chart

Key facts today

Viking Therapeutics, Inc. (VKTX) shares experienced a 7.9% increase after Novo Nordisk's CagriSema experimental obesity therapy reported disappointing results in a phase 3 trial.
Analyze the impactAnalyze the impact

VKTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.71 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.94 USD
Net income (FY)
‪−85.89 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪108.05 M‬
Beta (1Y)
3.31

Employees


Employees (FY)
27
Change (1Y)
+6 +28.57%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−3.18 M‬ USD

About Viking Therapeutics, Inc.


Sector
Health Technology
CEO
Brian Lian
Headquarters
San Diego
Website
vikingtherapeutics.com
Founded
2012
FIGI
BBG006LGV869
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VKTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VKTX is 42.25 USD — it has increased by 1.83% in the past 24 hours. Watch Viking Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Viking Therapeutics, Inc. stocks are traded under the ticker VKTX.
VKTX stock has fallen by −11.96% compared to the previous week, the month change is a −19.83% fall, over the last year Viking Therapeutics, Inc. has showed a 133.55% increase.
We've gathered analysts' opinions on Viking Therapeutics, Inc. future price: according to them, VKTX price has a max estimate of 164.00 USD and a min estimate of 74.00 USD. Watch VKTX chart and read a more detailed Viking Therapeutics, Inc. stock forecast: see what analysts think of Viking Therapeutics, Inc. and suggest that you do with its stocks.
VKTX reached its all-time high on Feb 28, 2024 with the price of 99.41 USD, and its all-time low was 0.88 USD and was reached on Aug 2, 2017. View more price dynamics on VKTX chart.
See other stocks reaching their highest and lowest prices.
VKTX stock is 8.36% volatile and has beta coefficient of 3.31. Track Viking Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Viking Therapeutics, Inc. there?
Today Viking Therapeutics, Inc. has the market capitalization of ‪4.71 B‬, it has decreased by −5.10% over the last week.
Yes, you can track Viking Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Viking Therapeutics, Inc. is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
VKTX earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.24 USD resulting in a 9.42% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about Viking Therapeutics, Inc. earnings.
Viking Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
VKTX net income for the last quarter is ‪−24.94 M‬ USD, while the quarter before that showed ‪−22.25 M‬ USD of net income which accounts for −12.09% change. Track more Viking Therapeutics, Inc. financial stats to get the full picture.
No, VKTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 27.00 employees. See our rating of the largest employees — is Viking Therapeutics, Inc. on this list?
Like other stocks, VKTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viking Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Viking Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Viking Therapeutics, Inc. stock shows the neutral signal. See more of Viking Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.